Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin by David V Gold et al.
Gold et al. Molecular Cancer 2013, 12:143
http://www.molecular-cancer.com/content/12/1/143RESEARCH Open AccessMapping PAM4 (clivatuzumab), a monoclonal
antibody in clinical trials for early detection and
therapy of pancreatic ductal adenocarcinoma, to
MUC5AC mucin
David V Gold1*, Guy Newsome1, Donglin Liu2 and David M Goldenberg1,2Abstract
Background: PAM4, an antibody that has high specificity for pancreatic ductal adenocarcinoma (PDAC), compared
to normal pancreas, benign lesions of the pancreas, and cancers originating from other tissues, is being
investigated as a biomarker for early detection, as well as antibody-targeted imaging and therapy. Therefore, the
identity of the antigen bound by this monoclonal antibody (MAb) can provide information leading to improved
use of the antibody. Prior results suggested the antigen is a mucin-type glycoprotein rich in cysteine disulfide brid-
ges that provide stable conformation for the PAM4-epitope.
Methods: Indirect and sandwich enzyme immunoassays (EIA) were performed to compare and contrast the
reactivity of PAM4 with several anti-mucin antibodies having known reactivity to specific mucin species (e.g., MUC1,
MUC4, MUC5AC, etc.). Studies designed to block reactivity of PAM4 with its specific antigen also were performed.
Results: We demonstrate that MAbs 2-11 M1 and 45 M1, each reactive with MUC5AC, are able to provide signal in
a heterologous sandwich immunoassay where PAM4 is the capture antibody. Further, we identify MAbs 21 M1,
62 M1, and 463 M1, each reactive with MUC5AC, as inhibiting the reaction of PAM4 with its specific epitope. MAbs
directed to MUC1, MUC3, MUC4, MUC16 and CEACAM6 are not reactive with PAM4-captured antigen, nor are they
able to block the reaction of PAM4 with its antigen.
Conclusions: These data implicate MUC5AC as a specific mucin species to which PAM4 is reactive. Furthermore,
this realization may allow for the improvement of the current PAM4 serum-based immunoassay for detection of
early-stage PDAC by the application of anti-MUC5AC MAbs as probes in this sandwich EIA.
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Mucin glycoproteins are high molecular weight, heavily
glycosylated, proteins that include at least 19 species cat-
egorized on the basis of their unique protein cores, and
can be found as either transmembrane components of
the cell or as secreted products. Abnormal expression of
mucins is a well-known occurrence in many forms of
cancer (see reviews [1-3]), including pancreatic ductal
adenocarcinoma (PDAC) [4-6]. Neo-expression and/or* Correspondence: dvgold@gscancer.org
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reproduction in any medium, provided the orupregulation/downregulation of specific mucin species,
with and without the generation of newly transcribed and
translated splice variants [7], have been well-documented
in the literature. Alteration of carbohydrate moieties
through the addition of new terminal sugars (e.g., neur-
aminic acids), underglycosylation, and other abnormal
biochemical pathways also have been observed [8-10].
These modifications may lead to changes in conform-
ational structure and/or appearance or disappearance of
specific epitopes. Additionally, changes may be observed
for the intracellular distribution of the mucin species
under consideration, such as MUC1, which in normal tis-
sues is a transmembrane glycoprotein, but with neoplasticd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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These events may prove to be of biological and clinical
significance in the process of neoplastic development and
progression, as well as provide new biomarkers/targets for
early detection and targeted therapy of cancer.
Our laboratory initially reported the use of a poly-
clonal antiserum to identify a pancreatic ductal mucin,
which at the level of sensitivity provided by indirect
immunohistochemistry (IHC), was shown to contain an
epitope relatively specific to the pancreas [13], and ultim-
ately resulted in the development of monoclonal antibody
(MAb), PAM4 [14], also known as clivatuzumab, the hu-
manized form. PAM4 demonstrates high specificity for
PDAC with little to no reactivity towards normal and be-
nign, non-neoplastic, pancreatic tissues, although it does
show limited reactivity (approximately 10% of all speci-
mens examined) with adenocarcinomas originating in
certain other organs (e.g., stomach, colon, lung) [14-16].
PAM4 identifies a biomarker that, if present, provides a
high diagnostic likelihood of the presence of pancreatic
neoplasia [16-18]. Thus, clinical applications for detection
of early-stage disease [16,18], and antibody-targeted im-
aging and therapy, are being pursued [19,20]. In addition
to PDAC, the PAM4-biomarker is expressed in the pre-
cursor lesions, pancreatic intraepithelial neoplasia (PanIN,
including the earliest developing lesion, PanIN-1A), and
intraductal papillary mucinous neoplasia (IPMN), sug-
gesting that there may be oncogenic significance to itsFigure 1 Reactivity of several anti-mucin MAbs with a high molecular
Capan-1 human pancreatic adenocarcinoma. MAbs are identified by clo
beneath MAb clone names (MUC1, etc.). In addition to PAM4, substantial re
bodies. All MAbs were employed at a concentration of 10 μg/mL.expression [15]. In the current study, we investigated
the identity of the mucin species to which this clinically-
relevant antibody is reactive, in order to understand what
role this mucin may play in the development and progres-
sion of pancreatic cancers.
Results
Several MAbs were evaluated by the indirect EIA for re-
activity with plates coated with CPM1 (Figure 1), a high
molecular weight mucin fraction isolated from the Capan-
1 human pancreatic cancer xenograft. Murine PAM4 and
MAbs reactive specifically with MUC1 and MUC5AC
mucins provided elevated reactivity in this indirect im-
munoassay, with minor reactivity also observed for MAbs
directed to MUC3 and CEACAM6. Essentially no reaction
was seen with MAbs to MUC2, MUC4, MUC16, and
CEACAM5 glycoproteins, or the CA19-9 carbohydrate
epitope. It should be noted that a negative EIA reaction
does not necessarily indicate absence of the mucin-
antigen, because the specific epitope structure may be
present, but inaccessible (i.e., cryptic). This is likely the
case for MAb-CLH2 anti-MUC5AC generated against a
peptide derived from the mucin's tandem repeat [21],
since the other two anti-MUC5AC MAbs are highly react-
ive. Similarly, CM1 anti-MUC1 was considerably less
reactive than MA5 and KC4 anti-MUC1 antibodies.
Capan-1 cells produce well-differentiated tumors with
highly glycosylated mucins. Thus, it is likely that bothweight mucin containing fraction (CPM1) isolated from the
ne name with reactive species of mucin indicated by horizontal bars
actions were observed for anti-MUC1, -MUC5AC, and -CEACAM6 anti-
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of their respective mucins, would not be reactive with
CPM1, since the tandem repeat epitopes are inaccessible.
We then evaluated whether the anti-mucin MAbs were
reactive with PAM4-captured mucin. Humanized PAM4
(hPAM4; clivatuzumab)-coated plates were used to cap-
ture the specific mucin-antigen from the CPM1 fraction,
which was then probed with various anti-mucin MAbs.
Murine MAbs (mMAbs) specifically reactive with MUC1,
MUC3, MUC4, MUC16 and CEACAM6 did not provide
a signal in these heterologous sandwich immunoassays.
On the other hand, both anti-MUC5AC mMAbs tested,
45 M1 and 2-11 M1, gave positive reactions with the
hPAM4-captured antigen (Figure 2), with 45 M1 showing
significantly greater reaction than 2-11 M1 (Kd = 14.32 ±
1.08 μg/mL and 24.4 ± 7.83 μg/mL, respectively, for MAbs
45 M1 and 2-11 M1; P < 0.001). However, neither of these
individual anti-MUC5AC MAbs provided as strong
signal intensity as the rabbit anti-CPM1 polyclonal IgG
fraction. Importantly, mPAM4 did not bind to the
hPAM4-captured antigen, nor did hPAM4 bind to
mPAM4-captured antigen, suggesting that the PAM4
epitope is present at low density, possibly only a single
site within the mucin-antigen.
Follow-up studies were designed to inhibit the binding
of hPAM4 to CPM1-coated plates (Figure 3). Although
2-11 M1 anti-MUC5AC was unable to inhibit hPAM4-
CPM1 binding, 45 M1 anti-MUC5AC did provide a
limited inhibitory effect, with ICmax = 25.5% inhibition.
mPAM4, included as a positive control, provided ICmax =
92.4% self-inhibition at a concentration 0.1 μg/mL, while
the MA5 and KC4 anti-MUC1 antibodies provided no
inhibition, even at the highest concentration evaluated
(10 μg/mL). hPAM4 was unable to completely block
mPAM4 binding to the CPM1 antigen (ICmax = 52.8%), a
not unexpected finding since the humanized version ofFigure 2 Reaction of several anti-mucin MAbs with PAM4-captured an
then probed with several murine anti-mucin MAbs for reaction signal. Both
captured mucin, whereas the anti-MUC1 MAbs (MA5 and KC4) did not bind
no signal, suggesting the density of PAM4 epitopes within the mucin may
was used as a positive control for reaction with hPAM4-captured antigen.PAM4 may have a lower affinity than the murine parent.
Ascites fluids containing mMAbs with known mapping to
MUC5AC were serially diluted as inhibitory reagents, with
results shown in Figure 3B. mMAbs 21 M1, 62 M1, and
463 M1 each provided inhibition similar to the results
shown for mPAM4 self-blocking, with 45 M1 ascites pro-
viding limited inhibition, similar to what was observed
with the commercially available 45 M1-IgG. Ascites fluid
containing a murine anti-alpha-fetoprotein (AFP) MAb,
included here as a negative control, provided no inhibition
of the hPAM4 binding to CPM1. Unfortunately, insuffi-
cient volumes of ascites precluded determination of MAb
concentrations, so that relative blocking efficiency could
not be calculated.
Epitopes for MAbs 21 M1, 62 M1, and 463 M1 have
each been mapped to the C-terminal region of MUC5AC
(22). This suggested that PAM4 may also be reactive with
the C-terminal region of the mucin. Thus, preliminary
studies were conducted to transfect the human CFPAC
pancreatic cancer cell line with a plasmid encoding the
peptide M-MUC5AC-CH-long (23), from the C-terminal
region of MUC5AC. Western blots of the expressed pep-
tide showed positive reactivity for the control myc-tag and
the 45 M1 epitope, but not PAM4 (data not shown).
Discussion
The current studies suggest that PAM4 is reactive with
the MUC5AC mucin glycoprotein. Figure 4 presents a
map of the MUC5AC mucin domains with reactive epi-
topes indicated for several of the anti-MUC5AC MAbs
employed in our studies [22-24]. CLH2 is reactive with
the peptide core of the tandem repeat domain [21], and is
likely a cryptic epitope within the Capan-1 tumor-derived
MUC5AC. 2-11 M1 is reactive with the N-terminus of the
mucin [23], and 45 M1 at the furthest N-terminal region
of the cysteine-rich, C-terminus [24]. Both of these MAbstigen. Mucin antigens were captured on hPAM4 coated plates, and
anti-MUC5AC MAbs (2-11 M1 and 45 M1) bound to the hPAM4-
. The homologous hPAM4/mPAM4, capture/probe immunoassay gave
be low, possibly only a single site. A rabbit polyclonal anti-CPM1 IgG
Figure 3 Inhibition of hPAM4/antigen binding reaction by murine anti-mucin MAbs. A) Anti-mucin mMAbs (purified IgG) were added to
CPM1-coated plates as potential inhibitors prior to addition of hPAM4. mPAM4 provided almost complete inhibition of the reaction between
hPAM4 and antigen with the 45 M1 anti-MUC5AC providing limited inhibitory effect (ICmax = 25.5%). Neither 2-11 M1, anti-MUC5AC nor MA5 and
KC4, anti-MUC1 MAbs were able to inhibit the specific hPAM4/antigen reaction. B) A similar inhibition study was performed with several anti-
MUC5AC MAbs obtained as ascites fluids. MAbs 21 M1, 62 M1, and 463 M1, anti-MUC5AC provided substantial inhibitory effect, similar to that ob-
served with mPAM4 IgG self-inhibition. The ascites form of 45 M1 yielded an inhibitory effect similar to that of the purified IgG. Ascites containing
anti-alpha fetoprotein was employed as a negative control.
Figure 4 Representation of the domains of the MUC5AC glycoprotein with reactive epitopes indicated for several anti-MUC5AC MAbs.
(Derived from references [22,23,28]). Data derived by transfection with plasmid vectors containing the cDNA of the 3’-end of MUC5AC, along with
derivative cDNA vectors obtained by restriction enzyme digestion, have identified the location of specific epitopes for anti-MUC5AC MAbs
employed in the current studies. Specific blocking studies (Figures 3A and B) suggest the PAM4-epitope resides within the cysteine-rich
C-terminus domain.
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to MUCs 1, 3, 4, and 16 were not. We observed that
45 M1 provides a significantly greater signal response than
2-11 M1, suggesting a greater density of 45 M1-epitopes
than 2-11 M1-epitopes within CPM1. However, this may
simply be due to a loss of 2-11 M1 epitopes through
proteolytic digestion of the relatively non-glycosylated N-
terminus, and/or molecular shear of this very large glyco-
protein during purification. In any case, the 2-11 M1
antibody provided no inhibition of the hPAM4-CPM1
interaction, suggesting the epitope is located distant to the
PAM4-epitope. On the other hand, 45 M1 did inhibit the
hPAM4-CPM1 interaction, albeit only partially, suggesting
that the PAM4-epitope is within the C-terminal region of
the mucin or conformationally altered by interaction of
this antibody with the mucin molecule. MAbs 21 M1,
62 M1, and 463 M1 also have been mapped to the C-
terminal region of the MUC5AC mucin [22-24], and each
provided significant inhibition of the PAM4-mucin reac-
tion. Taken together, our data provide direct evidence that
PAM4 is reactive with the identical mucin (MUC5AC),
and that the PAM4 epitope is either directly-blocked, or
conformationally modified, by interaction of these MAbs
with the MUC5AC antigen.
Preliminary studies to confirm the C-terminus location
of the PAM4 epitope by transfection with a plasmid en-
coding the C-terminal peptide were, as yet, unrevealing.
Whereas the control anti-myc tag and 45 M1 antibodies
showed positive reactions with the expressed peptide,
PAM4 was negative. These data would suggest the
PAM4-epitope is different from the 45 M1-epitope, and
not located within the C-terminal region. However, as
with the EIAs described in the manuscript, a positive
signal can provide a meaningful interpretation, the spe-
cific epitope is expressed, but a negative response does
not necessarily provide useful information. There are
several possible explanations as to why PAM4 might give
a negative response: 1) The epitope conformation may be
altered in the expressed peptide as compared to the native
mucin, 2) the epitope may include carbohydrate that may
not be present and/or may be altered from the native state,
and 3) the epitope may reside within a non-C-terminus
domain, but is conformationally altered by reaction of
MAbs with the C-terminus, amongst several other possi-
bilities. We intend to continue exploration of these factors
in an effort to better define the PAM4-epitope.
We had initially reported that PAM4 was reactive with
the MUC1 mucin species [15,17,25]. This was based upon
MUC1-gene transfection studies, where PAM4 was ob-
served to react with the gene-transfected MUC1+ cell line,
but not the MUC1- parental cell line or vector control cell
lines. However, other evidence acquired since then has
questioned this interpretation, suggesting that MUC1
transfection may have upregulated other mucins as well.Prior results from our laboratory lend support to the
current findings. The PAM4 epitope was found to be
highly sensitive to mild reduction with dithiothreitol
(0.02 M, 15 min, 20°C) or heat (100°C, 2 min), suggesting
the epitope is peptide in nature, and highly dependent
upon a specific conformation of the protein core kept in-
tact by disulfide bridges [14]. This is unlikely to be MUC1
with all of the cysteines located within the transmembrane
domain of the mucin, but is consistent with the loss of
reactivity shown by several anti-MUC5AC MAbs upon re-
duction of the mucin antigen. Further, employing immuno-
histochemical methods, we reported that frequency of
expression and morphologic distribution of the PAM4-
epitope within PDAC and its precursor lesions shared
greater similarity to those described for MUC5AC than for
MUC1 [15].
As already noted, there is an extensive literature re-
garding the abnormal expression of mucin-type glyco-
proteins in association with, or as a consequence of, the
development and progression of malignancy [1-12]. As-
pects of this research effort have been directed towards
both an understanding of the potential role of mucins in
tumor biology, and as a means to identify what is hoped
to be clinically-relevant biomarkers/targets for early detec-
tion and therapy of malignancy. Unfortunately, there ex-
ists a considerable amount of contradictory information
regarding expression of specific mucin species, due mostly
to differences in the methods used to detect and identify
the mucin. Detection of mucins by MAbs reactive to dif-
ferent epitopes within the identical mucin species or use
of different primer sets for RT-PCR can provide contra-
dictory results for expression of mucin species within ma-
lignant and benign lesions. For the present study, this is
highlighted by the positive response of MAbs PAM4, 2-
11 M1, and 45 M1 with CPM1-derived MUC5AC, in con-
trast to the limited response obtained with MAb-CLH2.
Considering that Capan-1 is a well-differentiated tumor
with highly glycosylated mucins [26], it is not unexpected
that the underlying tandem repeat peptide identified by
CLH2 might be cryptic and therefore not detectable.
Thus, expression of specific mucin species is related to the
method used for its detection.
Both the 2-11 M1 and 45 M1 MAbs were generated
against a mucin derived from a human ovarian mucin-
ous cyst [23,27], CLH2 [21] was generated against the
MUC5AC tandem repeat peptide, and each is able to
discriminate normal and malignant pancreatic tissues by
immunohistochemistry. High frequency detection of PDAC
and limited to no reactivity with normal pancreas tissue has
provided considerable interest for use of MUC5AC as a
biomarker of PDAC. However, MUC5AC, as detected by
these MAbs, does not show organ specificity, and is
expressed within several normal adult tissues (e.g., gastric,
colonic and lung mucosa, amongst others), and to varying
Table 1 Monoclonal antibodies used in the current
studies
Antigen Clone name Source
MUC1 MA5 Immunomedics
MUC1 KC4 Immunomedics
MUC1 CM1 Gene Tex
MUC2 994/152 Abcam
MUC3 M3.1 Abcam
MUC3 M3A LifeSpan Bio
MUC4 8G7 Santa Cruz Biotech
MUC5AC 2-11 M1 Santa Cruz Biotech
MUC5AC 45 M1 Santa Cruz Biotech
MUC5AC CLH2 Santa Cruz Biotech




CA 19-9 CA 19-9 Santa Cruz Biotech
Immunomedics, Inc. – Morris Plains, NJ; GeneTex – Irvine, CA; Abcam –
Cambridge, MA; LifeSpan Biosciences, Inc. - Seattle, WA; Santa Cruz Biotechnol-
ogy, Inc. - Santa Cruz, CA; Novus Biologicals – Littleton, CO.
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and others (e.g., lung adenocarcinoma and PDAC).
Although not directly compared in a single assay for-
mat with the same specimen set, it appears that the
PAM4-epitope demonstrates a higher specificity to dis-
criminate malignant from benign, non-neoplastic lesions
of the pancreas and, importantly, cancers originating from
other organs, than these other MAbs. The specific struc-
tural element of the PAM4-epitope responsible for this is
of particular interest. We have presented considerable evi-
dence, including immunohistochemical studies of tissue
specimens [14-16], as well as results from immunoassays
of patient sera [16-18], showing that PAM4 is reactive with
a biomarker that may have clinical relevance for the
detection and diagnosis of early-stage PDAC. The current
serum-based immunoassay employs PAM4 as the capture
component and a polyclonal anti-CPM1 IgG as the probe.
With the information provided from the present studies,
we may be able to substitute anti-MUC5AC MAbs (in par-
ticular, the 45 M1 MAb, since the PAM4 and 45 M1 epi-
topes are clearly distinct, yet both present within the same
molecule), for the rabbit polyclonal anti-CPM1 IgG cur-
rently employed as the probe. This could provide a more
suitable immunoassay for clinical use, since the rabbit poly-
clonal is limited in quantity with potential problems in lot-
to-lot consistency, whereas the anti-MUC5AC MAbs are
well defined and available for consistent application. How-
ever, the anti-MUC5AC MAbs would have to at least
match the sensitivity and specificity provided by the poly-
clonal probe. Such studies are in progress.
Conclusions
The use of MAbs having defined reactivity with MUC5AC
has identified two that are able to provide a signal response
in the heterologous PAM4 sandwich EIA, and three that
are able to inhibit the interaction between PAM4 and its
mucin antigen. These data implicate MUC5AC as the anti-
gen to which PAM4 is reactive. However, it should be
pointed out that these studies do not negate the possibility
that PAM4 is also reactive with other MUC-species. It is
certainly possible that two or more MUC-species can share
the same epitope. The significance of our current finding is
that MUC5AC contains an epitope structure which is
newly expressed early in the development of pancreatic
neoplasia. Whether or not this epitope structure represents
a reactive site for activation of oncogenesis in the pancreas
is as yet unknown. Nevertheless, this epitope can serve as a
biomarker for PDAC, as well as a target for antibody-
directed imaging and therapy.
Methods
Antigen and antibodies
A mucin-containing fraction, designated CPM1, was iso-
lated, as described previously [17], from the Capan-1human PDAC xenograft in athymic nude mice. Briefly, this
consisted of homogenization of the dissected tumor in
0.1 M ammonium bicarbonate containing 0.5 M sodium
chloride. Following high-speed centrifugation (20,000 g ×
45 min), the soluble material was chromatographed on a
Sepharose 4B-CL column, and then eluted with the
identical ammonium bicarbonate-sodium chloride solu-
tion. The void volume material was collected, dialyzed
against 0.01 M sodium phosphate, pH 7.2, and then
passed through hydroxyappatite to remove nucleic acids
and proteins. The non-binding, mucin-containing frac-
tion was again dialyzed extensively to remove salts and
used as a source of antigen.
Antibodies used in the current study are listed in
Table 1 with clone and source information. For sandwich
and blocking studies, PAM4 was available in both mur-
ine (mPAM4) and humanized (hPAM4; clivatuzumab)
versions provided by Immunomedics, Inc. (Morris Plains,
NJ). All other MAbs were murine IgG. Mouse ascites fluids
containing MAbs 21 M1, 45 M1, 62 M1 and 463 M1 were
kindly provided by Dr. J. Bara, INSERM, Paris, France.
PAM4 antibodies and ascites fluid containing an anti-
alpha-fetoprotein antibody, employed as a negative control
for the blocking studies (reactive with Hep-G2, hepatocel-
lular carcinoma cells) were provided by Immunomedics,
Inc. (Morris Plains, NJ). A rabbit polyclonal anti-CPM1
[14,16] IgG served as the positive control with detection by
a horseradish peroxidase (HRP)-labeled donkey anti-rabbit
IgG (Jackson ImmunoResearch, West Grove, PA).
Gold et al. Molecular Cancer 2013, 12:143 Page 7 of 8
http://www.molecular-cancer.com/content/12/1/143Enzyme immunoassay
Procedures have been described for both indirect and
sandwich enzyme immunoassays [14,16]. For indirect
immunoassays, primary MAbs were used at a concentra-
tion of 10 μg/mL to provide high sensitivity for signal
detection. For sandwich immunoassays, the capture
MAb was coated onto the wells at a concentration of
10 μg/mL, followed by the addition of the CPM1 antigen
at various concentrations up to 10 μg/mL. The MAb
probe was then added at a high concentration of 10 μg/
mL for detection of response to captured antigen. Sec-
ondary HRP-labeled anti-species-specific IgG (Jackson
ImmunoResearch, West Grove, PA) was evaluated ini-
tially to determine optimum concentrations for use in
the assay (usually 1:1000 or 1:2000). MAb inhibition
studies were performed by adding the inhibiting MAb to
wells coated with CPM1 antigen, starting at a high con-
centration of 100 μg/mL of pure MAb or 1:10 dilution
of ascites fluid, and titrating to lower amounts. After in-
cubating with the inhibiting antibody at 37°C for 1 h, the
plates were washed, and hPAM4 added to the wells at a
concentration of 0.25 μg/mL. hPAM4 binding was then
detected with a secondary probe, HRP-labeled anti-
human IgG conjugate.
Recombinant expression of MUC5AC C-terminal domains
The plasmid of pSM-MUC5AC-CH-long, encoding a sig-
nal sequence, a Myc tag, the complete human MUC5AC
C-terminal cysteine-rich part, and a His tag, is a gift from
Dr. Gunnar C. Hansson (University of Gothenburg,
Gothenburg, Sweden) [28]. CFPAC-1 cell line was obtained
from American Type Culture Collection (Manassas, VA)
and maintained in ATCC-formulated Iscove's Modified
Dulbecco's Medium plus 10% FBS at 37°C in 5% CO2.
Transfection was performed using Lipofectamine 2000
(Life Technologies, Grand Island, NY) when cells
reached about 85% confluent. Seventy-two hours later,
the spent medium was collected and 10-fold concen-
trated using 10 kD Amicon ultrafiltration membrane
(EMD Millipore, Billerica, MA). The recombinant pro-
teins were purified using an anti-Myc column (Vector
laboratories, Burlingame, CA) from the concentrated
medium.
SDS-PAGE and western-blot
SDS-PAGE was performed under non-reducing condi-
tions using 4-20% Tris-Glycine gels (Lonza, Allendale,
NJ) at 125 V for about 2 h. Resolved proteins were trans-
ferred onto a nitrocellulose membrane using the Mini
Trans-Blot® cell system (Bio-Rad Laboratories, Hercules,
CA) at 100 V for 1 h. To examine the identity of recom-
binant proteins, triplicate samples were run in the same
gel and membrane with transferred samples cut into three
pieces for probing with HRP-anti-Myc, HRP-hPAM4, and45 M1 plus HRP-GAM, respectively. The signals were de-
veloped with SuperSignal™ West Dura Chemiluminescent
Substrate (Thermo Fisher Scientific, Waltham, MA).
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